These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 595605)

  • 1. Low molecule and middle molecule metabolites with haemodynamic activity in the ultrafiltrate from uraemic patients (author's transl).
    Pogglitsch H; Petek W; Waller J; Stübchen-Kirchner H
    Wien Klin Wochenschr; 1977 Dec; 89(24):812-9. PubMed ID: 595605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of middle molecular weight fraction in the plasma of patients with uremia using high performance liquid chromatography and thin layer chromatography].
    Kovalishin IaF; Nikolaev VG; Baran EIa; Dudar' IA; Iushko LA
    Vopr Med Khim; 1988; 34(6):23-6. PubMed ID: 3238937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Middle molecules separation from uraemic serum (author's transl)].
    Dall'aglio P; Buzio C; Gardini GP; Migone L
    Ateneo Parmense Acta Biomed; 1975; 46(5):331-44. PubMed ID: 1236694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [An effect of chromatographic fraction ultrafiltrate of plasma on aggregation of blood platelets in patients with chronic uremia].
    Popławski A; Myśliwiec M
    Pol Merkur Lekarski; 1996 Oct; 1(4):246-8. PubMed ID: 9156935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uremic middle molecules: analytical study of middle molecular weight fractions subpeak b4-2.
    Le Moel G; Strecker G; Cueille G; Boudet J; Man NK; Galli A; Agneray J
    Artif Organs; 1981; 4 Suppl():17-21. PubMed ID: 7295087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrafiltration for middle molecules in uraemia.
    Reiger J; Quellhorst E; Lowitz HD; Kong RG; Scheler F
    Proc Eur Dial Transplant Assoc; 1975; 11():158-64. PubMed ID: 812083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired sympathetic response before intradialytic hypotension: a study based on spectral analysis of heart rate and pressure variability.
    Pelosi G; Emdin M; Carpeggiani C; Morales MA; Piacenti M; Dattolo P; Cerrai T; Macerata A; L'abbate A; Maggiore Q
    Clin Sci (Lond); 1999 Jan; 96(1):23-31. PubMed ID: 9857103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood level of middle molecular substances during uraemia and haemodialysis.
    Dzúrik R; Bozek P; Reznícek J; Oborníková A
    Proc Eur Dial Transplant Assoc; 1973; 10(0):263-70. PubMed ID: 4802412
    [No Abstract]   [Full Text] [Related]  

  • 10. Characterization of middle molecule compounds.
    Zimmerman L; Jörnvall H; Bergström J; Fürst P; Sjövall J
    Artif Organs; 1981; 4 Suppl():33-6. PubMed ID: 7295092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indolic tryptophan metabolism in uraemia.
    Byrd DJ; Berthold HW; Trefz KF; Kochen W; Gilli G; Schärer K; Schüler HW; Asbach HW
    Proc Eur Dial Transplant Assoc; 1976; 12():347-54. PubMed ID: 935125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Separation of peptides of "middle" molecular weight from biological fluids of patients with uremia.
    Fürst P; Bergström J; Gordon A; Johnsson E; Zimmerman L
    Kidney Int Suppl; 1975 Feb; (3):272-5. PubMed ID: 1057698
    [No Abstract]   [Full Text] [Related]  

  • 13. beta 2-Microglobulin and other low molecular weight proteins in haemodiafiltrates and in haemofiltrates.
    Montali U; Pilone N; Cioni L; Ronca G
    Int J Tissue React; 1984; 6(1):71-4. PubMed ID: 6370888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and metabolic consequences of uremic toxicity].
    Rutkowski P
    Przegl Lek; 2006; 63(4):209-17. PubMed ID: 17080744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment time and ultrafiltration rate are more important in dialysis prescription than small molecule clearance.
    Twardowski ZJ
    Blood Purif; 2007; 25(1):90-8. PubMed ID: 17170543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of urine metabolites from healthy and uremic subjects on gluconeogenesis in slices of rat kidney cortex and liver.
    Lamberts B; Brunner H; Ochs HG; Spellerberg P; Heintz R
    Clin Nephrol; 1976 Nov; 6(5):465-72. PubMed ID: 991468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term haemodialysis treatment with sodium removal by convection.
    Locatelli F; Pedrini L; Ponti R; Costanzo R; Di Filippo S; Marai P; Pozzi C; Bonacina GP
    Proc Eur Dial Transplant Assoc; 1981; 18():146-52. PubMed ID: 7329962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of clinical implications of middle molecules and their kinetics in uremia.
    Funck-Brentano JL; Man NK
    Artif Organs; 1981; 4 Suppl():125-32. PubMed ID: 7295078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.